TI Trust Inc. Boosts Stock Holdings in Eli Lilly and Company (NYSE:LLY)

TI Trust Inc. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,280 shares of the company’s stock after acquiring an additional 150 shares during the quarter. Eli Lilly and Company accounts for about 1.2% of TI Trust Inc.’s portfolio, making the stock its 21st largest position. TI Trust Inc.’s holdings in Eli Lilly and Company were worth $1,760,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Algert Global LLC increased its holdings in Eli Lilly and Company by 27.9% in the second quarter. Algert Global LLC now owns 504 shares of the company’s stock valued at $456,000 after buying an additional 110 shares during the last quarter. Pathway Financial Advisers LLC increased its holdings in Eli Lilly and Company by 4.2% in the second quarter. Pathway Financial Advisers LLC now owns 1,101 shares of the company’s stock valued at $982,000 after buying an additional 44 shares during the last quarter. Advisory Alpha LLC increased its holdings in Eli Lilly and Company by 6.5% in the second quarter. Advisory Alpha LLC now owns 3,208 shares of the company’s stock valued at $2,905,000 after buying an additional 195 shares during the last quarter. Ted Buchan & Co purchased a new position in Eli Lilly and Company in the second quarter valued at $1,780,000. Finally, Granite Bay Wealth Management LLC purchased a new position in Eli Lilly and Company in the second quarter valued at $323,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $804.87 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market cap of $764.08 billion, a P/E ratio of 87.01, a PEG ratio of 1.59 and a beta of 0.41. Eli Lilly and Company has a 52 week low of $637.00 and a 52 week high of $972.53. The company has a 50-day moving average price of $778.30 and a 200 day moving average price of $847.30.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.10 EPS. Research analysts predict that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company declared that its Board of Directors has initiated a share buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.75%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Truist Financial increased their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Wolfe Research started coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. Barclays decreased their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Finally, Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $997.22.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.